PLSM News & Events

Pulsenmore announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 ordinary shares and ordinary warrants to purchase up to 1,562,500 ordinary shares in a private placement at a combined purchase price of $4.80 per ordinary share and accompanying warrant, representing a premium to the Nasdaq Minimum Price under Nasdaq rules. The gross proceeds from the offering are expected to be approximately $7.5M, before deducting placement agent commissions and other estimated offering expenses. The ordinary warrants will have an exercise price of $4.80 per share, will be exercisable immediately upon issuance, and will expire five years following the date of issuance. The pre-funded warrants will have at an exercise price of $0.0001 per share and will be exercisable immediately until exercised in full. The closing of the Offering is expected to occur on or about June 26. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.

Pulsenmore Ltd. Ordinary Shares trading halted, volatility trading pause

Pulsenmore announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women's ultrasound practice in Maryland, as part of its growing U.S. rollout. In early February Pulsenmore, through its U.S. subsidiary, entered into a services agreement with TLC Perinatal PA, which operates in Silver Spring and Germantown, Maryland. Under the agreement, TLC Perinatal will incorporate Pulsenmore's Early Screening home ultrasound services into its care model, allowing patients to perform ultrasound scans at home as part of a physician-directed hybrid care pathway that incorporates telehealth and scheduled in-clinic visits. TLC Perinatal is a specialized maternal-fetal medicine practice focused on diagnostic imaging and consultative care for pregnancies.